Citadel Advisors’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-15,800
| Closed | -$117K | – | 14352 |
|
|
2026
Q1 | $117K | Buy |
+15,800
| New | +$103K | ﹤0.01% | 11879 |
|
|
2025
Q1 | – | Sell |
-800
| Closed | -$5.38K | – | 15094 |
|
|
2024
Q4 | $5.38K | Buy |
800
+740
| +1,233% | +$5.51K | ﹤0.01% | 13873 |
|
|
2024
Q3 | $464 | Sell |
60
-10
| -14% | -$60 | ﹤0.01% | 14014 |
|
|
2024
Q2 | $420 | Buy |
70
+10
| +17% | +$76 | ﹤0.01% | 13998 |
|
|
2024
Q1 | $541 | Sell |
60
-20
| -25% | -$182 | ﹤0.01% | 14317 |
|
|
2023
Q4 | $758 | Sell |
80
-2,860
| -97% | -$25.1K | ﹤0.01% | 13946 |
|
|
2023
Q3 | $35K | Sell |
2,940
-540
| -16% | -$9.57K | ﹤0.01% | 12149 |
|
|
2023
Q2 | $85.3K | Buy |
3,480
+2,720
| +358% | +$70.8K | ﹤0.01% | 11158 |
|
|
2023
Q1 | $23.8K | Buy |
760
+670
| +744% | +$38.8K | ﹤0.01% | 12926 |
|
|
2022
Q4 | $6.34K | Sell |
90
-2,130
| -96% | -$158K | ﹤0.01% | 13927 |
|
|
2022
Q3 | $191K | Sell |
2,220
-11,640
| -84% | -$1.13M | ﹤0.01% | 10447 |
|
|
2022
Q2 | $1.15M | Buy |
13,860
+9,390
| +210% | +$828K | ﹤0.01% | 6720 |
|
|
2022
Q1 | $743K | Buy |
+4,470
| New | +$642K | ﹤0.01% | 8422 |
|
|
2021
Q1 | – | Sell |
-1,330
| Closed | -$69K | – | 13489 |
|
|
2020
Q4 | $69K | Buy |
+1,330
| New | +$74K | ﹤0.01% | 10428 |
|
Citadel Advisors's KZR Position: Q2 2026 in Review
Citadel Advisors sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 59,403 shares — an estimated $441K sold.
Citadel Advisors first reported a position in KZR in Q1 2019 and held it in 26 quarters. The position peaked at $4.14M in Q1 2022. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- Citadel Advisors reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 59,403 Kezar Life Sciences shares in Q2 2026, an estimated $441K.
- Citadel Advisors first reported a position in Kezar Life Sciences in Q1 2019 and held it in 26 quarters.
- Citadel Advisors's Kezar Life Sciences position peaked at $4.14M in Q1 2022.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.